TY - JOUR T1 - <em>TG-Interacting Factor 1</em> expression quantitatively impacts survival in acute myeloid leukemia JF - medRxiv DO - 10.1101/2020.02.04.20020537 SP - 2020.02.04.20020537 AU - Ling Yan AU - Julie A. Means-Powell AU - Danko Martincic AU - Vladimir D. Kravtsov AU - Yu Shyr AU - John P. Greer AU - Utpal P. Davé AU - Mark J. Koury AU - David Wotton AU - Rizwan Hamid AU - Stephen J. Brandt Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/06/2020.02.04.20020537.abstract N2 - Applying transcriptional profiling analysis to myeloblasts from 59 adult patients with acute myeloid leukemia (AML) treated at our institution, we found that expression of the three-amino acid loop extension (TALE) homeobox gene TG-Interacting Factor 1 (TGIF1) correlated with overall and relapse-free survival, which was then confirmed in two other cohorts of patients.Moreover, TGIF1 expression correlated with survival for all cytogenetic risk groups and was an independent prognostic factor in multivariate analysis. To elucidate the mechanism, we used Tgif1 knockout mice in which acute or chronic myeloid leukemia was induced through retroviral transfer of the MLL-AF9 or BCR-ABL fusion genes into bone marrow cells. Loss of Tgif1 accelerated disease progression, shortened survival, attenuated the response to chemotherapy, and doubled the frequency of leukemia-initiating cells. RNA-based sequencing analysis showed that genes associated with transforming growth factor-β (TGF-β) and retinoic acid signaling pathways were differentially affected in Tgif1-/- compared to Tgif1+/+ leukemia cells.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is funded by NIHAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData included in the manuscript ER -